VeriMom¿Es borago officinalis leaf extract seguro durante el embarazo?
No EU Cosmetic Regulation ban (Annex II) or Annex III restriction or harmonised CLP H360/H361 was identified for Borago officinalis leaf extract. However, the plant family (Boraginaceae) is known to produce pyrrolizidine alkaloids (PAs) which have demonstrated toxic and genotoxic mechanisms in animals and humans; this represents a class-based concern (h=1) with a demonstrated mechanism (m=2). Topical cosmetic use of a leaf extract is likely low but measurable exposure (e=1). Sources: EU INCI listing for Borago Officinalis Extract, PubMed reviews on borage/PAs, and EWG ingredient summary.
Alternativas seguras a borago officinalis leaf extract en el embarazo | VeriMom
Related ingredients
Frequently asked questions
- ¿Es borago officinalis leaf extract seguro durante el embarazo?
- No EU Cosmetic Regulation ban (Annex II) or Annex III restriction or harmonised CLP H360/H361 was identified for Borago officinalis leaf extract. However, the plant family (Boraginaceae) is known to produce pyrrolizidine alkaloids (PAs) which have demonstrated toxic and genotoxic mechanisms in animals and humans; this represents a class-based concern (h=1) with a demonstrated mechanism (m=2). Topical cosmetic use of a leaf extract is likely low but measurable exposure (e=1). Sources: EU INCI listing for Borago Officinalis Extract, PubMed reviews on borage/PAs, and EWG ingredient summary.
- ¿Es borago officinalis leaf extract seguro durante la lactancia?
- Same rationale as pregnancy: no regulatory ban or harmonised reproductive classification found, but PA-related hepatotoxic/genotoxic concerns for Borago officinalis warrant a class-level caution (h=1). Mechanistic evidence for PA toxicity exists (m=2). Topical use implies low but measurable exposure (e=1); systemic transfer into breastmilk after dermal cosmetic use has not been demonstrated.
- ¿Es borago officinalis leaf extract seguro para la piel del bebé?
- Hazard (h=1) remains driven by the plant’s PA class concern rather than any infant-specific reproductive data. Mechanistic concern from PAs (m=2) remains. Exposure is increased for babies (elevated by +1 to e=2) because infant skin has higher surface-area-to-weight and an immature barrier, so topical absorption (if any) is proportionally higher even though absolute systemic exposure from a cosmetic extract is expected to be low.
- ¿Cómo puntúa VeriMom a borago officinalis leaf extract?
- VeriMom puntúa borago officinalis leaf extract en 60/100 (riesgo medio) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a borago officinalis leaf extract en el embarazo?
- Consulta nuestra lista de alternativas seguras a borago officinalis leaf extract según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.